Several drug companies have pledged to include a broad representation of people in their COVID-19 vaccine clinical trials as they prepare to launch studies with thousands of volunteers in the coming months, as reported in This is Money.
"Ensuring diversity in these trials, including in terms of race, ethnicity, gender, age, and other factors, is a priority in our efforts," said Menelas Pangalos, AstraZeneca's head of biopharmaceutical R&D, ahead of a hearing held by the US House subcommittee on oversight and investigations.
Early data from trials of three potential COVID-19 vaccines released earlier this week, including a closely watched candidate from AstraZeneca and Oxford University, increased confidence that a vaccine can induce immune responses against SARS-CoV-2.
To read more NewsPoints articles, click here.
About FirstWord Pharma | Upgrade Your FirstWord Pharma | Contact FirstWord Pharma | FirstWord Reports
Advertise with FirstWord Pharma | Industry Partner Showcase
All Contents Copyright © 2021 Doctor's Guide Publishing Limited. All Rights Reserved.
Terms of Use | Privacy Policy